BHC - Bausch Health Companies Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
23.54
+0.28 (+1.20%)
As of 2:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close23.26
Open23.37
Bid23.56 x 1000
Ask23.57 x 800
Day's range23.30 - 23.72
52-week range17.20 - 28.45
Volume1,293,290
Avg. volume3,791,336
Market cap8.322B
Beta (3Y monthly)2.11
PE ratio (TTM)N/A
EPS (TTM)-4.61
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date2010-11-10
1y target est30.93
Trade prices are not sourced from all markets
  • CNW Group6 days ago

    Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets

    BRIDGEWATER, N.J. and NEW YORK , July 17, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031 . Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd, had challenged the validity of and had alleged non-infringement of Claims 2 and 5 of U.S. Patent No. 8,524,276, which protects the formulation of RELISTOR® tablets. Bausch Health is not aware of any other ANDAs filed with the FDA seeking approval of a generic version of RELISTOR tablets, and will continue to vigorously defend its intellectual property in these and other claims.

  • Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall
    Zacks7 days ago

    Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall

    Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

  • Is Bausch Health (BHC) a Great Value Stock Right Now?
    Zacks13 days ago

    Is Bausch Health (BHC) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Aerie Completes Enrollment Under Rhopressa Study in Japan
    Zacks14 days ago

    Aerie Completes Enrollment Under Rhopressa Study in Japan

    Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

  • CNW Group14 days ago

    Bausch + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins

    BRIDGEWATER, N.J. , July 9, 2019 /CNW/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Ocuvite® Eye Performance vitamins, a nutritional supplement designed to meet the changing needs of consumers while further expanding the company's eye vitamin portfolio. "Today's modern, always-on world has evolved faster than our eyes – from the blue light of computer screens and cell phones to the increased UV exposure from the sun – which can have an impact on our eye health," said Joe Gordon , U.S. president, Bausch + Lomb.

  • CNW Group15 days ago

    Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

    Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

  • Is Bausch Health Becoming a Successful Turnaround Story?
    Market Realist18 days ago

    Is Bausch Health Becoming a Successful Turnaround Story?

    Bausch Health (BHC) has gained 20.13% in the last month and is up by 38.93% in 2019 on a YTD basis.

  • Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
    Zacks18 days ago

    Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

    Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

  • Why Shares of Bausch Health Companies Rocketed Higher in June
    Motley Fool19 days ago

    Why Shares of Bausch Health Companies Rocketed Higher in June

    It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.

  • Here's Why Dova Pharmaceuticals Stock Jumped Higher Today
    Motley Fool26 days ago

    Here's Why Dova Pharmaceuticals Stock Jumped Higher Today

    The drugmaker's Doptelet therapy just received an expanded approval.

  • Dova Receives Approval for Doptelet in Europe, Stock Up
    Zacks26 days ago

    Dova Receives Approval for Doptelet in Europe, Stock Up

    Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

  • Zacks28 days ago

    Allergan Up As Analyst Statement Sparks Business Split Rumors

    Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

  • CNW Group28 days ago

    Bausch Health To Reduce Debt By Additional $100 Million Using Cash Generated From Operations

    LAVAL, Quebec , June 25, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash generated from operations. After this payment, the Company will have eliminated all mandatory amortization for the first quarter of 2020. Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

  • CNW Group28 days ago

    Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

    LAVAL, Quebec , June 25, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration on April 25, 2019 , DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation. "The launch of DUOBRII marks the fifth innovative therapy that Ortho Dermatologics has brought forward within the last 30 months," said Bill Humphries , president, Ortho Dermatologics.

  • Barrons.com29 days ago

    Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.

    It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).

  • Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%
    Zackslast month

    Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%

    Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • CNW Grouplast month

    Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

    BRIDGEWATER, N.J. , June 19, 2019 /CNW/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the company's unique 3-Zone Progressive ™ multifocal design with the stability of its OpticAlign® toric design to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.

  • Why Is Bausch (BHC) Down 16.2% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Bausch (BHC) Down 16.2% Since Last Earnings Report?

    Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • CNW Group2 months ago

    Bausch Health Companies Announces Participation in Upcoming Investor Conferences

    Bausch Health Companies Announces Participation in Upcoming Investor Conferences

  • CNW Group2 months ago

    Bausch Health Announces Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes

    LAVAL, Quebec , May 23, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of its outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on May 24, 2019 (the "Early Settlement Date"). The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 9, 2019 (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Letter of Transmittal.

  • Better Turnaround Play: Bausch Health Companies or Teva Pharmaceutical Industries
    Motley Fool2 months ago

    Better Turnaround Play: Bausch Health Companies or Teva Pharmaceutical Industries

    Which of these fallen stars has the more compelling comeback story?